vasopressin + epinephrine + methylprednisolone

Vasopressin + epinephrine + methylprednisolone (VSE) is a combination therapy investigated by the National Taiwan University Hospital for the treatment of out-of-hospital cardiac arrest (OHCA). This triple-drug regimen, evaluated in the OHCA REVIVES trial, is designed to improve the rates of sustained return of spontaneous circulation (ROSC) and long-term survival compared to standard epinephrine monotherapy. The combination leverages the synergistic effects of three distinct agents: vasopressin, which acts as a potent non-adrenergic vasoconstrictor via V1 receptors; epinephrine, which provides alpha- and beta-adrenergic stimulation to increase coronary and cerebral perfusion pressure; and methylprednisolone, a corticosteroid intended to suppress the post-cardiac arrest systemic inflammatory response and improve hemodynamics. The therapy is typically administered by advanced paramedics in the prehospital setting during resuscitation efforts.

Other names

vasopressin, epinephrine, and methylprednisoloneVSE combinationVSE therapy